Serum levels of apoptosis inhibitor of macrophage are associated with hepatic fibrosis in patients with chronic hepatitis C.
Serum levels of apoptosis inhibitor of macrophage are associated with hepatic fibrosis in patients with chronic hepatitis C.
复制标题
DOI：
10.1186/1471-230x-14-27
复制
发表时间：
2014-02-13
影响因子：
2.4
通讯作者：
Tsubouchi H
中科院分区：
文献类型：
--
作者：
Mera K;Uto H;Mawatari S;Ido A;Yoshimine Y;Nosaki T;Oda K;Tabu K;Kumagai K;Tamai T;Moriuchi A;Oketani M;Shimada Y;Hidaka M;Eguchi S;Tsubouchi H
巨噬细胞凋亡抑制剂 (AIM) 和脂肪细胞因子参与代谢综合征，推测代谢综合征与慢性丙型肝炎 (CHC) 的进展有关。然而，这些细胞因子与 CHC 之间的关联尚未完全阐明。本研究的目的是测试 CHC 患者的血清 AIM 和脂肪细胞因子水平是否与组织学特征、稳态模型评估胰岛素抵抗指数 (HOMA-IR) 或全身胰岛素敏感性指数 (WBISI) 相关。血清样本取自 77 名经活检证实患有 CHC 的患者。在 39 名没有明显糖尿病的患者中，进行了 75 g 口服葡萄糖耐量试验 (OGTT)，并计算了 HOMA-IR 和 WBISI。根据多变量分析，血清 AIM 水平≥1.2 μg/ml 与晚期肝纤维化（F2 或 F3）独立相关（优势比 [OR]，5.612；95% 置信区间 [CI]，1.103–28.563；P = 0.038），但 AIM 与肝脂肪变性或炎症之间没有显着关联。此外，血清瘦素水平≥8.6ng/ml与肝脂肪变性（≥5%）独立相关（OR，6.195；95%CI，1.409-27.240；P = 0.016），但与肝纤维化或炎症无关。根据多变量分析，未观察到脂联素或抵抗素水平与肝组织学参数之间存在关系。尽管血清瘦素、抵抗素和脂联素水平与 HOMA-IR 和 WBISI 显着相关，但血清 AIM 水平分别与 HOMA-IR 或 WBISI 之间不存在显着相关性。 CHC 患者血清 AIM 水平升高可能与晚期肝纤维化有关。 AIM 和脂肪细胞因子可能通过不同的机制与病理变化相关。
Apoptosis inhibitor of macrophage (AIM) and adipocytokines are involved in the metabolic syndrome, which has been putatively associated with the progression of chronic hepatitis C (CHC). However, the association between these cytokines and CHC is not fully elucidated. The aim of this study is to test whether serum levels of AIM and adipocytokines are associated with histological features, homeostasis model assessment-insulin resistance index (HOMA-IR), or whole body insulin sensitivity index (WBISI) in CHC patients. Serum samples were obtained from 77 patients with biopsy-proven CHC. In 39 patients without overt diabetes mellitus, a 75 g oral glucose tolerance test (OGTT) was performed and HOMA-IR and WBISI were calculated. A serum AIM level of ≥1.2 μg/ml was independently associated with advanced hepatic fibrosis (F2 or F3) (odds ratio [OR], 5.612; 95% confidence interval [CI], 1.103–28.563; P = 0.038) based on a multivariate analysis, but there was no significant association between AIM and hepatic steatosis or inflammation. Furthermore, a serum leptin level of ≥8.6 ng/ml was independently associated with the presence of hepatic steatosis (≥5%) (OR, 6.195; 95% CI, 1.409–27.240; P = 0.016), but not hepatic fibrosis or inflammation. No relationship was observed between levels of adiponectin or resistin and hepatic histological parameters based on a multivariate analysis. Although serum levels of leptin, resistin, and adiponectin were significantly correlated with HOMA-IR and WBISI, there was no significant relationship between serum AIM levels and HOMA-IR or WBISI, respectively. High serum levels of AIM in CHC patients are potentially related to advanced hepatic fibrosis. AIM and adipocytokines are possibly associated with pathological changes via a different mechanism.